Background: The use of central nervous system (CNS) acting drugs in the management of
neuro degenerative and psychiatric problems cannot be overemphasized. Therefore, the chemical
structure of piroxicam can be modified to yield new CNS stimulants and depressants that can be of
great benefit to man and animals.
Methodology: Acetylcholine has Methyl - Oxygen-Oxygen (M-O-O) and Nitrogen (N) functional
groups which are structurally related to Sulphur-Oxygen-Oxygen (S-O-O) and Nitrogen (N) of piroxicam
that are either methylated or hydrogenated. Each arecoline and nicotine has M-O-O in addition to
methylated nitrogen and pyridine ring respectively, making them structurally related to piroxicam.
Therefore, when Sulphur of piroxicam is replaced by methyl group, it may likely have muscarinic effects
expressed by glandular secretion, gut sedation and vasodepression. Whereas the nitrogen group
may be responsible for cholinergic effect in gaglia and striated muscle. Because of the carboxylic
functional group (COOH), piroxicam may display depressant effect. Hence C = O, C = N and C = C
in piroxicam may change due to biofield treatement.
Conclusion: The conversion of piroxicam to central nervous system (CNS) acting drugs may be by
desulphation, methylation, dehydrogenation, carboxylation and carbonylation. The would-be synthesized
CNS drugs from piroxicam, should have low molecular weight, lipid solubility and low PH.